• 秦超

    药剂系 副教授
    领域:缓控释制剂产业化,新型药物递送系统
    联系电话:
    电子邮箱:nada77@163.com
    办公室:江宁校区学院实验楼432室
    实验室:江宁校区学院实验楼430北
  • 1、教育经历
    (1) 2011/09-2014/06,中国药科大学, 药物代谢动力学,博士
    2012/03-2014/03 北京大学, 药学院
    (2) 2011/09-2014/07, 中国药科大学, 药剂学, 硕士
    (3) 1998/09-2002/07, 中国药科大学, 中药学, 学士
    2、工作经历
    (1) 2019/07 至今, 中国药科大学, 药学院, 副教授
    (2) 2014/07-2019/06, 中国药科大学, 药学院, 讲师
    3、学术荣誉
    2020/08,江苏省科技副总
    4、学术兼职
    2021/05,中国抗生素杂志青年编委
    2018/09,药剂学青年学者论坛专家委员会后备委员
    (1) 口服固体制剂(缓控释制剂及速释制剂研发及产业化)
    (2) 智能纳米微粒给药系统及产业化
    (3) 纳米制剂同生物体相互作用
    1、科研项目
    (1)科技部,重大新药创制科技重大项目,2017ZX09101001,药物一致性评价关键技术与标准研究,2018-01-01 至 2021-06-30,88.235万元(到账),已结题,参与
    (2)国家自然科学基金委员会,自然科学基金杰出青年基金项目,81503011,间接抑制受体相关蛋白以增强抗肿瘤转移效果的靶向脂质体的构建及机制研究,2016.01.01至2018.12.30, 17.9万元,已结题,主持
    (3)科技部,重大新药创制科技重大项目,2014ZX09507004,口服缓控释关键技术及新产品产业化,2014-01-01 至 2016-12-30,90万元(到账),已结题,参与
    (4)委托研究项目,校合2022-药007,2022.01.01至2027.12.30,100万元(到账),在研,主持
    (5)委托研究项目,校合2020-药037,2020.04.30至2030. 04.30,100万元(到账),在研,参与
    1.Zhang, P.1; Qin, C1.; Liu, N.; Zhou, X.; Chu, X.; Lv, F.; Gu, Y.; Yin, L.; Liu, J.; Zhou, J.; Huo, M., The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment. Biomaterials 2022, 284, 121518. (IF: 12.479)
    2.Ruan, Y.; Li, X.; You, L.; Chen, J.; Shen, Y.; Zhang, J.; Yuan, Y.; Kang, L.; Qin, C.*; Wu, C.*, Effect of Pharmaceutical Excipients on Intestinal Absorption of Metformin via Organic Cation-Selective Transporters. Molecular pharmaceutics 2021, 18 (6), 2198-2207. (IF: 4.939)
    3.Qin, C.; Yang, X.; Wu, Y. B.; Lv, Y. Q.; Zhang, L.; Xin, X. F.; Yang, L.; He, W.; Han, X. P.; Yin, L. F.; Wu, C. Y., Matrix metalloproteinases sensitive multifunctional micelles for inhibition of metastatic tumor growth and metastasis. Powder Technol 2019, 358, 3-12. (IF: 4.142)
    4.Zhu, C.; Xu, S.; Han, X.; Wang, W.; He, W.; Yin, L.; Yang, L.*; Qin, C.*, Sustained Release Bilayer Tablet of Ibuprofen and Phenylephrine Hydrochloride: Preparation and Pharmacokinetics in Beagle Dogs. AAPS PharmSciTech 2019, 20 (2), 86. (IF: 3.473)
    5.Han, X. P.; Yan, J. C.; Ren, L. J.; Xue, M. L.; Yuan, Z. Y.; Wang, T. T.; Yan, Z.; Yin, L. F.; Yang, L.*; Qin, C.*, Preparation and evaluation of orally disintegrating film containing donepezil for Alzheimer disease. J Drug Deliv Sci Tec 2019, 54. (IF: 2.608)
    6.Han, X. P.; Zhang, S.; Chai, Z. D.; Dong, Y. Y.; He, W.; Yin, L. F.; Yang, L.*; Qin, C.*, In vitro and in vivo evaluation of the taste-masking efficiency of Amberlite IRP88 as drug carries in chewable tablets. J Drug Deliv Sci Tec 2019, 49, 547-555. (IF: 2.608)
    7.Qin, C.; Lv, Y. Q.; Xu, C. R.; Li, J. J.; Yin, L. F.; He, W., Lipid-bilayer-coated nanogels allow for sustained release and enhanced internalization. Int J Pharm 2018, 551 (1-2), 8-13. (IF: 4.213)
    8.Qin, C.; Wu, M.; Xu, S.; Wang, X.; Shi, W.; Dong, Y.; Yang, L.; He, W.; Han, X.; Yin, L., Design and optimization of gastro-floating sustained-release tablet of pregabalin: In vitro and in vivo evaluation. Int J Pharm 2018, 545 (1-2), 37-44. (IF: 4.213)
    9.Qin, C.; Xin, X.; Pei, X.; Yin, L.; He, W., Amorphous Nanosuspensions Aggregated from Paclitaxel (-) Hemoglobulin Complexes with Enhanced Cytotoxicity. Pharmaceutics 2018, 10 (3). (IF: 4.773)